- For adults with acute respiratory distress syndrome (ARDS), surfactant treatment does not reduce mortality or improve oxygenation, according to the results of this meta-analysis.
Why this matters
- ARDS often features deficient surfactant.
- Adult trials of surfactant administration have yielded mixed results.
- ARDS mortality reaches as high as 46%.
- Mortality with surfactant vs without: risk ratio, 1.02 (95% CI, 0.93-1.12; P=.65).
- Mortality showed no significant between-group differences whether measured at 7-10, 28-30, or 90-180 days.
- PaO2/FiO2 ratio with surfactant vs without: mean difference, 0.06 (95% CI, −0.12 to 0.24; P=.5).
- No publication bias detected.
- Meta-analysis of 11 randomized controlled trials that compared pulmonary surfactant vs standard therapy in adults with ARDS (n=3038).
- Outcome: mortality.
- Funding: Chinese national and provincial funds.
- Small sample sizes.
- Some bias risks.
- Surfactants and treatment duration differed among trials.